Treatment for Multidrug-Resistant Tuberculosis (MDR-TB)
For adolescents ≥14 years and adults with MDR/RR-TB, use the 6-month BPaLM regimen (bedaquiline, pretomanid, linezolid, and moxifloxacin) as first-line treatment. This represents the most significant advance in MDR-TB therapy and is strongly recommended by the most recent 2025 ATS/CDC/ERS/IDSA guidelines 1.
Primary Treatment Approach: 6-Month Short-Course Regimens
The treatment landscape has fundamentally shifted from 18-20 month regimens to 6-month all-oral options:
First-Line: BPaLM Regimen (6 months)
- Indication: Rifampin-resistant, fluoroquinolone-susceptible pulmonary TB in patients ≥14 years 1
- Composition: Bedaquiline + Pretomanid + Linezolid + Moxifloxacin
- Strength: Strong recommendation despite very low certainty evidence 1
- Key advantage: Dramatically shorter duration with high cure rates
Alternative: BPaL Regimen (6 months)
- Indication: Rifampin-resistant TB with fluoroquinolone resistance OR intolerance 1
- Composition: Bedaquiline + Pretomanid + Linezolid (without moxifloxacin)
- Requirement: No previous exposure to bedaquiline/linezolid >1 month 1
Expanded Population Option: BDLLfxC Regimen (6 months)
- Composition: Bedaquiline + Delamanid + Linezolid + Levofloxacin + Clofazimine
- Critical advantage: Can be used in children of all ages, pregnant/breastfeeding women 2, 3
- Key difference: Replaces pretomanid with delamanid, expanding eligible populations 3
When Short-Course Regimens Are NOT Appropriate
You must use longer 18-20 month individualized regimens when:
- Extensive bilateral cavitary disease or extensive parenchymal damage on chest X-ray 4
- Severe extrapulmonary TB: CNS TB, miliary TB, disseminated disease, osteoarticular TB 4, 3
- Previous exposure to second-line drugs >1 month 4
- Confirmed resistance to fluoroquinolones AND bedaquiline or linezolid (XDR-TB) 5
Critical pitfall: The 6-month regimens lack sufficient clinical data for complicated extrapulmonary forms, particularly CNS and bone involvement, due to theoretical concerns about drug penetration 3.
Longer Individualized Regimens (18-20 months)
When short-course regimens are contraindicated, construct regimens using the WHO grouping system 4:
Drug Selection Algorithm:
Include ALL three Group A agents (if susceptible):
Add at least one Group B agent:
If only 1-2 Group A agents available: Use BOTH Group B agents 4
Add Group C agents if needed to ensure ≥4 effective drugs:
What NOT to Use:
- Avoid kanamycin and capreomycin entirely 4
- Avoid ethionamide/prothionamide and p-aminosalicylic acid unless no better options exist 4
- Never use clavulanic acid (strong recommendation against) 4
Duration Specifics:
- Total duration: 18-20 months for most patients 4
- Alternative calculation: 15-17 months after culture conversion 4
- Injectable phase (if amikacin/streptomycin used): 6-7 months 4
Special Populations
Children and Adolescents
- Ages ≥14 years: Use adult regimens (BPaLM or BPaL) 1
- Ages 6-17 years: Bedaquiline may be included in longer regimens 4
- All ages: BDLLfxC regimen is an option 2, 3
Pregnant and Breastfeeding Women
- BDLLfxC regimen is specifically recommended for this population 2, 3
- Treatment principles remain the same as general MDR-TB patients 2
HIV Co-infection
- Same anti-TB regimen design principles as HIV-negative patients 2
- Initiate antiretroviral therapy within 8 weeks of starting TB treatment (regardless of CD4 count) 2
- Exception: CNS TB—delay ART to 4-8 weeks after TB treatment initiation 2
- Carefully assess drug-drug interactions between antiretrovirals and anti-TB drugs 2
Monitoring Requirements
Do not modify short-course regimens except for linezolid-related adverse events—these are fixed, standardized combinations 2. Dose adjustments are permitted for toxicity, but drug substitution requires expert consultation 2.
For longer regimens, ideally perform monthly sputum smear and culture during treatment 2. Short-course regimens may require more frequent monitoring 2.
Critical Implementation Points
The evidence supporting 6-month regimens is rated as "very low certainty" yet carries strong recommendations 1, 4, reflecting the dramatic improvement in treatment duration and tolerability over historical 18-20 month regimens. This represents a paradigm shift prioritizing quality of life and treatment completion.
Essential prerequisite: Confirm fluoroquinolone susceptibility before using BPaLM or BDLLfxC regimens, as fluoroquinolone resistance is an absolute contraindication to these specific regimens 1, 4. Molecular diagnostics for rapid resistance detection are critical 4.
Treatment should ideally occur in specialized centers or with expert consultation given the complexity and low case numbers in many settings 5.